U.S. flag

An official website of the United States government

NM_000152.5(GAA):c.546+5G>T AND Glycogen storage disease, type II

Germline classification:
Uncertain significance (8 submissions)
Last evaluated:
Oct 4, 2022
Review status:
3 stars out of maximum of 4 stars
reviewed by expert panel
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000673997.20

Allele description [Variation Report for NM_000152.5(GAA):c.546+5G>T]

NM_000152.5(GAA):c.546+5G>T

Gene:
GAA:alpha glucosidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000152.5(GAA):c.546+5G>T
HGVS:
  • NC_000017.11:g.80105137G>T
  • NG_009822.1:g.8582G>T
  • NM_000152.5:c.546+5G>TMANE SELECT
  • NM_001079803.3:c.546+5G>T
  • NM_001079804.3:c.546+5G>T
  • LRG_673t1:c.546+5G>T
  • LRG_673:g.8582G>T
  • NC_000017.10:g.78078936G>T
  • NM_000152.3:c.546+5G>T
  • NM_000152.4(GAA):c.546+5G>T
  • NM_000152.4:c.546+5G>T
Links:
dbSNP: rs756024023
NCBI 1000 Genomes Browser:
rs756024023
Molecular consequence:
  • NM_000152.5:c.546+5G>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001079803.3:c.546+5G>T - intron variant - [Sequence Ontology: SO:0001627]
  • NM_001079804.3:c.546+5G>T - intron variant - [Sequence Ontology: SO:0001627]

Condition(s)

Name:
Glycogen storage disease, type II (GSD2)
Synonyms:
ACID ALPHA-GLUCOSIDASE DEFICIENCY; GLYCOGENOSIS, GENERALIZED, CARDIAC FORM; GSD II; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0009290; MedGen: C0017921; Orphanet: 365; OMIM: 232300

Recent activity

  • Homo sapiens
    Homo sapiens
    The transcriptome effect of overexpressing EZH2 in MCF7
    BioProject

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000799265Counsyl
criteria provided, single submitter

(Counsyl Autosomal Recessive and X-Linked Classification Criteria (2018))
Uncertain significance
(Apr 6, 2018)
unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

Citation Link,

SCV000964244Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Dec 9, 2023)
germlineclinical testing

PubMed (10)
[See all records that cite these PMIDs]

SCV001423031Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard
criteria provided, single submitter

(ACMG Guidelines, 2015)
Likely pathogenic
(Jan 22, 2020)
germlinecuration

PubMed (3)
[See all records that cite these PMIDs]

Citation Link,

SCV001810285Genome-Nilou Lab
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Jul 22, 2021)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV002091931Natera, Inc.
no assertion criteria provided
Likely pathogenic
(Oct 20, 2020)
germlineclinical testing

SCV002817437ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel
reviewed by expert panel

(clingen_lsd_acmg_specifications_v2-1)
Uncertain significance
(Oct 4, 2022)
germlinecuration

PubMed (1)
[See all records that cite this PMID]

Citation Link,

SCV002819909Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Pathogenic
(Dec 30, 2022)
germlineclinical testing

PubMed (2)
[See all records that cite these PMIDs]

Citation Link,

SCV004195479Baylor Genetics
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(Feb 21, 2024)
unknownclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedunknownunknownnot providednot providednot providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing, curation
not providedgermlinenonot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.

Buratti E, Chivers M, Královicová J, Romano M, Baralle M, Krainer AR, Vorechovsky I.

Nucleic Acids Res. 2007;35(13):4250-63. Epub 2007 Jun 18.

PubMed [citation]
PMID:
17576681
PMCID:
PMC1934990

Statistical features of human exons and their flanking regions.

Zhang MQ.

Hum Mol Genet. 1998 May;7(5):919-32.

PubMed [citation]
PMID:
9536098
See all PubMed Citations (13)

Details of each submission

From Counsyl, SCV000799265.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000964244.6

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (10)

Description

This sequence change falls in intron 2 of the GAA gene. It does not directly change the encoded amino acid sequence of the GAA protein. RNA analysis indicates that this variant induces altered splicing and is likely to result in the loss of the initiator methionine. This variant is present in population databases (rs756024023, gnomAD 0.05%). This variant has been observed in individual(s) with Pompe disease (PMID: 21232767). ClinVar contains an entry for this variant (Variation ID: 557811). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 2, and is expected to result in the loss of the initiator methionine (PMID: 31301153). This variant disrupts the p.Arg190 amino acid residue in GAA. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 21484825, 23000108, 24444888, 29149851, 31076647). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard, SCV001423031.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (3)

Description

The c.546+5G>T variant in GAA has been reported in at least two Taiwanese individuals with glycogen storage disease (PMID: 20080426, 21232767), and has been identified in 0.050% (9/18078) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs756024023). Although this variant has been seen in the general population, its frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar as a VUS by Counsyl (VariationID: 557811). This variant is located in the 5' splice region. Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The phenotype of individuals homozygous and compound heterozygous for this variant is highly specific for glycogen storage disease based on enzyme activity in in lymphocytes and fibroblasts being <10% of controls, consistent with disease (PMID: 21232767). Additionally, the presence of this variant in combination with a reported likely pathogenic variant p.Tyr360Ter, as well as a homozygous occurrence (PMID: 21232767), in individuals with glycogen storage disease increases the likelihood that the c.546+5G>T variant is pathogenic. In summary, although additional studies are required to fully establish its clinical significance, this variant is likely pathogenic. ACMG/AMP Criteria applied: PM3, PM2, PP4_moderate, PP3 (Richards 2015).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Genome-Nilou Lab, SCV001810285.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenonot providednot providednot providednot providednot providednot providednot provided

From Natera, Inc., SCV002091931.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel, SCV002817437.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (1)

Description

The NM_000152.5:c.546+5G>T variant is an intronic variant in exon 2 of GAA. The variant has been found in multiple patients identified by newborn screening programs in Taiwan and Japan (PMID: 20080426, 21232767, 31076647, 34995642). However, the variant always occurs in cis with pseudodeficiency variants (including c.1726G>A) which could be responsible for the reduced GAA activity. One patient, who was compound heterozygous for the variant and c.1080C>G (p.Tyr360Ter), was reported to have initial CK elevation, and hypotonia for the first few years of life, but was later reported as "normal" by the family at age 13 years (PMID: 34995642). Another patient was homozygous for the variant (PMID: 21232767). In addition, patients who are heterozygous for the variant, with no second variant suspicious for causing Pompe disease, have been found. At the current time, the clinical significance of this variant is unclear. No patient with a clear diagnosis of Pompe disease has been found and it is unknown if this variant may contribute to later onset symptoms (neither PP4 nor PM3 were applied). The highest population minor allele frequency in gnomAD v2.1.1 is 0.0004978 in the East Asian population which is lower than ClinGen LSD VCEP threshold of <0.001 (PM2_supporting). RT-PCR of RNA from primary fibroblasts a patient who is compound heterozygous for c.[546+5G>T; 1726G>A] and c.1080C>G (p.Tyr360Ter) revealed a normal-sized fragment containing 2 sequences (1 normal and 1 with a 3-bp insertion) and an aberrantly short fragment containing a deletion of exon 2 (PMID: 34995642). Another study also showed, based on RT-PCR, that the variant results in skipping of exon 2 (PMID: 31301153). RT-PCR shows that variant results in skipping of exon 2, and is expected to result in the loss of the initiator methionine (PMID: 31301153), meeting PS3_supporting. There is ClinVar entry to this variant (Variation ID : 557811, one star review status) with five submitters classifying the variant as Pathogenic (1); Likely Pathogenic (1); Uncertain significance (2). In summary, this variant has been classified as a variant of uncertain significance for Pompe disease by the ClinGen Lysosomal Storage Disorders Variant Curation Expert Panel. GAA-Specific ACMG-AMP criteria applied, as specified by the ClinGen LSD VCEP (Specifications Version 2.0): PS3_supporting, PM2_supporting. (Classification approved by the ClinGen LSD VCEP on October 4, 2022).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV002819909.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (2)

Description

Variant summary: GAA c.546+5G>T alters a conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: Three predict the variant abolishes the canonical 5' splicing donor site. One predicts the variant weakens the canonical 5' splicing donor site. At least one publication reports experimental evidence that this variant affects mRNA splicing resulting in skipping of exon 2 (Goina_2019). The variant allele was found at a frequency of 3.8e-05 in 235344 control chromosomes. c.546+5G>T has been reported in the literature as a homozygous or compound heterozygous genotype in newborns affected with later onset Glycogen Storage Disease, Type 2 (Pompe Disease) (example, Chien_2011). These data indicate that the variant may be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function (Chien_2011). The most pronounced variant effect results in <10% of normal alpha glucosidase activity in lymphocytes and fibroblasts from a homozygous individual. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (P/LP, n=3; VUS, n=2). Based on the evidence outlined above, the variant was classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Baylor Genetics, SCV004195479.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1unknownunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024